News on COVID-19

Saiba GmbH, , has developed a proprietary platform technology based on immunologically optimized virus-like particles. This platform technology has now enabled scientists to establish preclinical proof-of-concept for a vaccine against COVID-19. The vaccine candidate has been able to induce in test animals high levels of antibodies that neutralize the novel corona virus. Induction of neutralizing antibodies is the goal of all anti-viral vaccines including vaccines against hepatitis B, human papilloma and polio virus. To our knowledge, this is the first such vaccine candidate. As the vaccine has been able to induce high levels of antibodies within a week in test animals, we hope that there might be an opportunity for therapeutic intervention. The novel vaccine candidate is based on the highly scalable CuMVtt vaccine platform and we expect to be able to produce millions to billions of doses in a relatively short time.

Recent Publications

[/b][b]Saiba scientists published in collaboration with different universities a number of ground-braking publications underscoring the power of the Saiba vaccination platform.

Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, Schwarz K, Johansen P, Jennings GT, Bachmann MF. Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes. Mol Ther Methods Clin Dev. 2014 Oct 22;1:14048. doi: 10.1038/mtm.2014.48. eCollection 2014.

Zabel F, Mohanan D, Bessa J, Link A, Fettelschoss A, Saudan P, Kündig TM, Bachmann MF. Viral particles drive rapid differentiation of memory B cells into secondary plasma cells producing increased levels of antibodies.
J Immunol. 2014 Jun 15;192(12):5499-508.

Cavelti-Weder C, Timper K, Seelig E, Keller C, Osranek M, Lässing U, Spohn G, Maurer P, Müller P, Jennings GT, Willers J, Saudan P, Donath MY, Bachmann MF.
Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes.
Mol Ther. 2016 May;24(5):1003-12.

Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M. Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Sci Rep. 2016 Jan 19;6:19234.

Zabel F, Fettelschoss A, Vogel M, Johansen P, Kündig TM, Bachmann MF. Distinct T helper cell dependence of memory B-cell proliferation versus plasma cell differentiation.. Immunology. 2016 Nov 9. doi: 10.1111/imm.12688 Impact: 3.6

Eduardo Alves, Ahmed M. Salman, Fabiana Leoratti, Cesar Lopez-Camacho, Martha Eva Viveros-Sandoval, Amar Lall, Aadil El-Turabi, Martin F. Bachmann, Adrian V.S. Hill, Chris J. Janse, Shahid M. Khan and Arturo Reyes-Sandoval. Evaluation of PvCelTOS as a pre-erythrocytic P. vivax vaccine. Clinical and Vaccine Immunology, 2017 Apr 5;24(4). pii: e00501-16. , impact: 2.5

Ana R. Cardoso, Gustavo Cabral-Miranda, Arturo Reyes-Sandoval, Martin F Bachmann and M. Goreti F. Sales. Detecting circulating antibodies by controlled surface modification with specific target proteins: Application to malaria. Biosensors and Bioelectronics. May 15;91:833-841. doi: 10.1016/j.bios.2017.01.031. Epub 2017 Jan 15. Impact: 7.8

Mohsen MO, Gomes AC, Cabral-Miranda G, Krueger CC, Leoratti FM, Stein JV, Bachmann MF. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. J Control Release. 2017 Apr 10;251:92-100. doi: 10.1016/j.jconrel.2017.02.031. Epub 2017 Feb 28. Impact: 6

Gomes AC, Flace A, Saudan P, Zabel F, Cabral-Miranda G, Turabi AE, Manolova V, Bachmann MF. Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines. Front Immunol. 2017 Mar 6;8:226. doi: 10.3389/fimmu.2017.00226. eCollection 2017 Mar 6. Impact:6.5

Doucet M, El-Turabi A, Zabel F, Hunn BHM, Bengoa-Vergniory N, Cioroch M, Ramm M, Smith AM, Gomes AC, Cabral de Miranda G, Wade-Martins R, Bachmann MF Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS One. 2017 Aug 10;12(8):e0181844. Impact: 4

Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells. Engeroff P, Caviezel F, Storni F, Thoms F, Vogel M, Bachmann MF.
Allergy. 2017 Aug 8. doi: 10.1111/all.13268. Impact: 6.5

Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines. Leneghan DB, Miura K, Taylor IJ, Li Y, Jin J, Brune KD, Bachmann MF, Howarth M, Long CA, Biswas S. Sci Rep. 2017 Jun 19;7(1):3811. Impact: 4.8

Cabral-Miranda G, Heath MD, Mohsen MO, Gomes AC, Engeroff P, Flaxman A, Leoratti FMS, El-Turabi A, Reyes-Sandoval A, Skinner MA, Kramer MF, Bachmann MF.Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. Vaccines (Basel). 2017 May 2;5(2). Impact: 1.8

Lisha Zha, Fabiana Leoratti, Federico Storni, Dr.Monique Vogel and
Martin Fabian Bachmann (2017). An unexpected protective role of low affinity allergen-specific IgG via the inhibitory receptor FcgRIIb. JACI, in press. Impact: 12.5

P. Engeroff, M. Fellmann, D. Yerly, M.F. Bachmann and M. Vogel (2017) IgE-dependent antigen recycling in human B cells facilitates transfer to dendritic cells and antigen presentation. JACI, in press. Impact: 12.5

Andris Zeltins, Jonathan West, Franziska Zabel, Aadil El-Turabi, Ina Balke, Stefanie Haas, Melanie Maudrich, Federico Storni, Paul Engeroff, Gary T Jennings, Abhay Kotecha, David I Stuart, John Foerster, Martin F Bachmann (2017) Incorporation of Tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy. Nature PJ Vaccines, in press

Gustavo Cabral-Miranda, Matthew D. Heath, Aadil El-Turabi, Ahmed M. Salman, Ariane C. Gomes, Eduardo Montoya-Diaz, Erwan Atcheson, Murray A Skinner, Matthias F. Kramer, Arturo Reyes-Sandoval, Martin F Bachmann (2017) Microcrystalline tyrosine (MCT): a depot adjuvant licensed in allergy offers new opportunities in malaria, Vaccines, in press. Impact: 1.8

Antonia Fettelschoss-Gabriel, Victoria Fettelschoss, Thomas M. Kündig, Martin F. Bachmann. (2018) Treating insect bite hypersensitivity (IBH) in horses by active vaccination against Interleukin-5 JACI, in press

Martin F. Bachmann, Andris Zeltins, Gints Kalnins, Ina Balke, Nina Fischer, Ana Rostaher Kaspars Tars, Claude Favrot (2018). Vaccination against IL-31 for the treatment of atopic dermatitis in dogs., JACI, in press

Cabral-Miranda G, Cardoso AR, Ferreira LCS, Sales MGF, Bachmann MF (2018) Biosensor-based selective detection of Zika virus specific antibodies in infected individuals. Biosens Bioelectron. 2018 Aug 15;113:101-107. doi: 10.1016/j.bios.2018.04.058. Epub 2018 May

Fettelschoss-Gabriel A, Fettelschoss V, Olomski F, Birkmann K, Thoms F, Bühler M, Kummer M, Zeltins A, Kündig TM, Bachmann MF. Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses.
Allergy. 2018 Nov 7. doi: 10.1111/all.13659.

Reviews and Commentaries:

Bachmann MF, Whitehead P. (2013) Active immunotherapy for chronic diseases.
Vaccine. 31:1777-84
Impact: 3.5

Reyes-Sandoval A, Bachmann MF. (2013) Plasmodium vivax malaria vaccines: Why are we where we are? Hum Vaccin Immunother. 9:.
Impact: 3.1

Zabel F., Kündig, TM and Bachmann MF. (2013) Virus-induced humoral immunity: on how B cell responses are initiated. Curr Opin Virol. 2013 3:357-62.
Impact: 2.5

Bachmann MF, Whitehead P. (2013) Active immunotherapy for chronic diseases.
Vaccine. 31:1777-84.
Impact: 3.5

Fettelschoss A, Zabel F, Bachmann MF. Vaccination against Alzheimer disease: an update on future strategies. Hum Vaccin Immunother. 2014;10(4):847-51.

Klimek L, Bachmann MF, Senti G, Kündig TM. Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Rev Clin Immunol. 2014 Aug;10(8):1059-67.

Kündig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF.
Is The Allergen Really Needed in Allergy Immunotherapy? Curr Treat Options Allergy. 2015;2(1):72-82.

Förster J and Bachmann MF. Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments Nanomedicine (Lond.) (2015) 10(8), 1361–1369
Bachmann MF, Kündig TM. Allergen specific immunotherapy: is it vaccination against toxins after all? Allergy. 2016 Aug 24.

Gomes AC, Mohsen M, Bachmann MF. Harnessing Nanoparticles for Immunomodulation and Vaccines. Vaccines (Basel). 2017 Feb 14;5(1). pii: E6. doi: 10.3390/vaccines5010006. Impact: 1.8

Pumpens P, Renhofa R, Dishlers A, Kozlovska T, Ose V, Pushko P, Tars K, Grens E, Bachmann MF. The True Story and Advantages of RNA Phage Capsids as Nanotools. Intervirology. 2016;59(2):74-110. Impact: 1.8

Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017 Sep 5. Impact: 9.6

Bachmann MF, Jennings GT, Vogel M. A vaccine against Alzheimer`s disease: anything left but faith? Expert Opin Biol Ther. 2019 Jan;19(1):73-78. doi: 10.1080/14712598.2019.1554646. Epub 2018 Dec 1

Engeroff P, Bachmann MF. The 5th Virus-like Particle and Nano-Particle Vaccines (VLPNPV) conference. Expert Rev Vaccines. 2018 Dec 10. doi: 10.1080/14760584.2019.1557522.

Bachmann MF, El-Turabi A, Fettelschoss-Gabriel A, Vogel M. The Prospects of an Active Vaccine Against Asthma Targeting IL-5. Front Microbiol. 2018 Oct 24;9:2522. doi: 10.3389/fmicb.2018.02522.

Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. Mohsen MO, Gomes AC, Vogel M, Bachmann MF.
Vaccines (Basel). 2018 Jul 2;6(3). pii: E37. doi: 10.3390/vaccines6030037